Home / Stock ratings / NBIX
Stock rating
Neurocrine Biosciences Inc (NBIX) Stock Rating & Analysis
As of October 13, 2026, MELANY rates Neurocrine Biosciences Inc 75 out of 100 (Highest Conviction). Its highest factor scores are earnings track record and catalyst setup at 92, and its lowest is price momentum at 46.
MELANY ratingRated 2026-10-13NBIX · composite score
Why NBIX scores 75/100
NBIX's 8 factor scores run from 46 to 92, and 4 of them sit above its composite of 75. Here is how NBIX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 19.8x vs sector 22.0x median
- Forward P/E 11.2x, earnings growth accelerating
- PEG ratio 0.28 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 64%
- ROE 22%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +37%
- Earnings in 20 days (strong beat history)
What Wall Street price targets and revisions are signalling.
- Analyst targets 53% upside
Near-term events that could move the stock.
- Earnings in 20 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for NBIX
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Neurocrine Biosciences Inc sits in the Healthcare sector theme, which MELANY currently rates 62/100 for strength. Theme strength feeds NBIX's momentum and catalyst factors above.
NBIX trade plan (Pro)
MELANY has a full position plan for Neurocrine Biosciences Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates NBIX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Neurocrine Biosciences Inc's 75/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about NBIX
Is Neurocrine Biosciences Inc (NBIX) a buy?
As of 2026-10-13, MELANY rated Neurocrine Biosciences Inc Highest Conviction with a composite score of 75/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Neurocrine Biosciences Inc's MELANY score?
Neurocrine Biosciences Inc (NBIX) has a MELANY composite score of 75/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the NBIX stock rating calculated?
MELANY scores NBIX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Neurocrine Biosciences Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Neurocrine Biosciences Inc (NBIX) Highest Conviction with a composite of 75/100 as of 2026-10-13. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the NBIX stock price forecast?
MELANY does not publish price targets or forecasts for NBIX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 75/100 across eight factors for Neurocrine Biosciences Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is NBIX stock overvalued or undervalued?
MELANY's valuation factor currently reads 71/100 for Neurocrine Biosciences Inc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives NBIX's read.
What price should I buy NBIX at?
Rather than chasing the current price, MELANY computes a smart entry zone for NBIX: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying NBIX stock?
The top risks MELANY currently flags for Neurocrine Biosciences Inc: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Neurocrine Biosciences Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 78/100 for Neurocrine Biosciences Inc, and earnings track record, at 92/100. The 75/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will NBIX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 46/100 for NBIX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this NBIX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-13. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores NBIX continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, NBIX included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.